visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity |
Data: | 2022 |
Resum: | Epidemiological studies have demonstrated the association between hepatitis B virus (HBV) infection and B-cell non-Hodgkin lymphoma (NHL), mainly for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). We studied a cohort of 121 patients with FL for HBV infection status, clinical features, and gene mutational profile. Anti-HBc was detectable in 16 patients (13. 2%), although all had undetectable HBV DNA. AntiHBcore (anti-HBc) cases presented with older age at diagnosis than anti-HBc cases (68. 1 vs 57. 2 years; P 5. 007) and higher b2-microglobulin (56. 3% vs 28. 9%; P 5. 04). All patients included in the study fulfilled criteria for treatment and received therapy with rituximab or rituximab-containing chemotherapy. There were no episodes of HBV reactivation or HBV hepatitis during treatment and/or maintenance. Remarkably, anti-HBc patients had significantly lower 10-year progression-free survival (PFS; 12. 9% vs 58. 3%; P,. 0001) and overall survival (OS; 22. 0% vs 86. 2%; P,. 0001), that remained at multivariate analysis. Gene mutational profiling of all cases showed that anti-HBc cases had higher incidence of ARID1A mutations and absence of EP300 mutations, 2 key epigenetic regulators in FL. Overall, our study shows that FL patients with resolved HBV infection have a worse outcome independently of other well-known clinical risk factors and a distinct gene mutational profile. |
Ajuts: | Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR205 Instituto de Salud Carlos III PI15/0459 Instituto de Salud Carlos III PI19/00034 |
Nota: | This study was supported in part by Instituto de Salud Carlos III FIS-FEDER PI15/0459, FIS-FEDER PI19/00034, GIL-EAD GLD18/00117, 2017SGR205, PT20/00023, and Xarxa de Banc de Tumors de Catalunya sponsored by Pla Director d'Oncologia de Catalunya. The authors also acknowledge the Biobank of the Fundación MD Anderson International supported by the Instituto de Salud Carlos III grant PT17/ 0015/0008. |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Publicat a: | Blood advances, Vol. 6 Núm. 1 (november 2022) , p. 82-86, ISSN 2473-9537 |
5 p, 801.1 KB |